The European Ombudsman, Emily O’Reilly, has asked the European Medicines Agency (EMA) why it agreed to keep large amounts of information hidden about clinical trials on the medicine Humira. AbbVie, the manufacturer of Humira, had sued the EMA to keep the information confidential. As part of a settlement announced in April, the EMA agreed to redact some of the trial information. Following the agreement, the Ombudsman began investigating if these redactions were legal. The Ombudsman has asked for a reply to her letter by 31st January 2015.

Read the Ombudsman’s letter to the EMA.